Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 12/20 | 0.62 |
| ▸ | KDM4E | B2RXH2 | 11/20 | 0.62 |
| ▸ | HPGD | P15428 | 8/20 | 0.62 |
| ▸ | HTT | P42858 | 5/20 | 0.60 |
| ▸ | MAPT | P10636 | 5/20 | 0.60 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.60 |
| ▸ | RCE1 | Q9Y256 | 1/20 | 0.60 |
| ▸ | TP53 | P04637 | 1/20 | 0.60 |
| ▸ | MEN1 | O00255 | 3/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.59 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.59 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.59 |
| ▸ | NPC1 | O15118 | 2/20 | 0.59 |
| ▸ | RAB9A | P51151 | 2/20 | 0.59 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.59 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.59 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.59 |
| ▸ | GFER | P55789 | 1/20 | 0.59 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL231419 | 0.98 | KDM4E (0.64) | ALDH1A1KDM4EHPGDHTTMAPT | |
| SCHEMBL230641 | 0.89 | ALDH1A1 (0.70) | ALDH1A1KDM4EHPGDHTTMAPT | |
| SCHEMBL6144594 | 0.87 | KDM4E (0.50) | ALDH1A1KDM4EHPGDHTTMAPT | |
| SCHEMBL11522697 | 0.87 | ALDH1A1 (0.69) | ALDH1A1KDM4EHPGDHTTMAPT | |
| SCHEMBL31551700 | 0.85 | KDM4E (0.48) | ALDH1A1KDM4EHPGDHTTMAPT | |
| SCHEMBL16692204 | 0.84 | KDM4E (0.69) | ALDH1A1KDM4EHPGDHTTMAPT | |
| SCHEMBL5009162 | 0.82 | KDM4E (0.77) | ALDH1A1KDM4EHPGDHTTMAPT | |
| SCHEMBL16692163 | 0.82 | KDM4E (0.66) | ALDH1A1KDM4EHPGDHTTMAPT | |
| SCHEMBL27985773 | 0.82 | KDM4E (0.51) | ALDH1A1KDM4EHPGDHTTMAPT | |
| SCHEMBL16692173 | 0.81 | KDM4E (0.69) | ALDH1A1KDM4EHPGDHTTMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1268371-A4 | NOVEL LATE TRANSITION METAL CATALYST COMPLEXES AND OLIGOMERS THEREFROM | EXXONMOBIL RES & ENG CO (US) | 2009-07-01 | — | — | EP | claimed |
| EP-1268371-A1 | NOVEL LATE TRANSITION METAL CATALYST COMPLEXES AND OLIGOMERS THEREFROM | ExxonMobil Research and Engineering Company (US) | 2003-01-02 | — | — | EP | claimed |
| US-6501000-B1 | CATALYTIC CONVERSION OF SHORT CHAIN ALPHA OLEFINS TO LONG CHAIN ALPHA OLEFINS; SELECTIVE, EFFICIENT; NICKEL, PALLADIUM OR PLATINUM WITH DINITROGEN CONTAINING BIDENTATE LIGAND | EXXONMOBIL RESEARCH AND ENGINEERING COMPANY | 2002-12-31 | — | — | US | claimed |
| WO-2001074743-A1 | NOVEL LATE TRANSITION METAL CATALYST COMPLEXES AND OLIGOMERS THEREFROM | EXXONMOBIL RESEARCH AND ENGINEERING COMPANY (US) | 2001-10-11 | — | — | WO | claimed |
| EP-1268371-A4 | NOVEL LATE TRANSITION METAL CATALYST COMPLEXES AND OLIGOMERS THEREFROM | EXXONMOBIL RES & ENG CO (US) | 2009-07-01 | — | — | EP | disclosed |
| EP-1492746-A1 | SELECTIVE COUPLING OF TERMINAL OLEFINS WITH ETHYLENE TO MANUFACTURE LINEAR ALPHA-OLEFINS | ExxonMobil Research and Engineering Company (US) | 2005-01-05 | — | — | EP | disclosed |
| US-6777584-B2 | USING ORGANOMETALLIC CATALYST | EXXONMOBIL RESEARCH AND ENGINEERING COMPANY | 2004-08-17 | — | — | US | disclosed |
| US-6689928-B2 | PREPARED IN SITU FROM A NICKEL, PALLADIUM OR PLATIINUM COMPOUND AND A NITROGEN-CONTAINING LIGAND; OLIGOMERIZING OLEFIN MONOMERS | EXXONMOBIL RESEARCH AND ENGINEERING COMPANY | 2004-02-10 | — | — | US | disclosed |
| US-20030166985-A1 | Selective coupling of terminal olefins with ethylene to manufacture linear alpha-olefins | EXXONMOBIL RESEARCH & ENGINEERING COMPANY | 2003-09-04 | — | — | US | disclosed |
| WO-2003072529-A1 | SELECTIVE COUPLING OF TERMINAL OLEFINS WITH ETHYLENE TO MANUFACTURE LINEAR ALPHA-OLEFINS | EXXONMOBIL RESEARCH AND ENGINEERING COMPANY (US) | 2003-09-04 | — | — | WO | disclosed |
| WO-2003027130-A2 | TRANSITION METAL COMPLEXES FOR PREPARING OLEFIN OLIGOMERS | EXXONMOBIL RESEARCH AND ENGINEERING COMPANY (US) | 2003-04-03 | — | — | WO | disclosed |
| EP-1268371-A1 | NOVEL LATE TRANSITION METAL CATALYST COMPLEXES AND OLIGOMERS THEREFROM | ExxonMobil Research and Engineering Company (US) | 2003-01-02 | — | — | EP | disclosed |
| US-6501000-B1 | CATALYTIC CONVERSION OF SHORT CHAIN ALPHA OLEFINS TO LONG CHAIN ALPHA OLEFINS; SELECTIVE, EFFICIENT; NICKEL, PALLADIUM OR PLATINUM WITH DINITROGEN CONTAINING BIDENTATE LIGAND | EXXONMOBIL RESEARCH AND ENGINEERING COMPANY | 2002-12-31 | — | — | US | disclosed |
| US-20020045790-A1 | Transition metal complexes and oligomers therefrom | EXXONMOBIL CHEMICAL PATENTS INC. | 2002-04-18 | — | — | US | disclosed |
| WO-2001074743-A1 | NOVEL LATE TRANSITION METAL CATALYST COMPLEXES AND OLIGOMERS THEREFROM | EXXONMOBIL RESEARCH AND ENGINEERING COMPANY (US) | 2001-10-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030166985-A1 | Selective coupling of terminal olefins with ethylene to manufacture linear alpha-olefins | EEF1D, CYP4Z1, ECH1 | ALDH1A1 2839/4885KDM4E 3528/4885HPGD 1251/4885 |
| US-20020045790-A1 | Transition metal complexes and oligomers therefrom | NCF1, ICOSLG, NPM1 | ALDH1A1 2791/4885KDM4E 4701/4885HPGD 1901/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.